In addition, chemotherapy resistance increased the level of terminally differentiated and immunosuppressive cells (i.e., SPP1+ and MRC1+ CCL18+ macrophages) while decreased the cytotoxic immune cells (i.e., FGFBP2+ GZMB+ CD8+ T cells) in liver metastases patients (64), providing evidence to support first-line use of ICIs for patients with LM. This evidence concerns the gene CCL18 and lymphangioma.